DENTSPLY SIRONA (XRAY) Stock Forecast & Price Target

Compare

573 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

XRAY Analyst Ratings

Hold

3 Buy

9 Hold

1 Sell

Based on 13 analysts giving stock ratings to

DENTSPLY

SIRONA

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

XRAY Stock 12 Month Forecast

Average Price Target

$14.90

▲(29.12% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for DENTSPLY SIRONA in the last 3 months. The average price target is $14.90 with a high forecast of $18.00 and a low forecast of $12.00. The average price target represents a 29.12% change from the last price of $11.54.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"10":"$10","19":"$19","12.25":"$12.25","14.5":"$14.5","16.75":"$16.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14.9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.90</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[10,12.25,14.5,16.75,19],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.31,14.593846153846155,14.877692307692309,15.161538461538463,15.445384615384615,15.72923076923077,16.013076923076923,16.296923076923076,16.58076923076923,16.864615384615384,17.14846153846154,17.432307692307692,17.716153846153844,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.31,14.355384615384615,14.400769230769232,14.446153846153846,14.491538461538463,14.536923076923078,14.582307692307692,14.627692307692309,14.673076923076923,14.718461538461538,14.763846153846155,14.80923076923077,14.854615384615386,{"y":14.9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,14.31,14.132307692307693,13.954615384615385,13.776923076923078,13.59923076923077,13.421538461538463,13.243846153846153,13.066153846153846,12.888461538461538,12.71076923076923,12.533076923076923,12.355384615384615,12.177692307692308,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.778,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.111,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.418,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.046,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.093,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.913,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.913,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.765,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.43,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.02,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.43,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.21,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.31,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$18.00

Average Price Target$14.90

Lowest Price Target$12.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kevin Caliendo

UBS

$16→$18

Buy

55.98%

Upside

Reiterated

03/02/26

Dentsply Sirona price target raised to $18 from $16 at UBSDentsply Sirona price target raised to $18 from $16 at UBS

Michael Petusky

Barrington

$14→$17

Buy

47.31%

Upside

Reiterated

03/02/26

Dentsply Sirona price target raised to $17 from $14 at BarringtonDentsply Sirona price target raised to $17 from $14 at Barrington

Steven Valiquette

Mizuho Securities

$14→$16

Hold

38.65%

Upside

Reiterated

03/02/26

Dentsply Sirona price target raised to $16 from $14 at MizuhoDentsply Sirona price target raised to $16 from $14 at Mizuho

Unknown Analyst

Wells Fargo

Not Ranked

Wells Fargo

$13

Hold

12.65%

Upside

Reiterated

02/27/26

Wells Fargo Keeps Their Hold Rating on DENTSPLY SIRONA (XRAY)

Jeff Johnson

Robert W. Baird

$12→$14

Hold

21.32%

Upside

Reiterated

02/27/26

Dentsply Sirona price target raised to $14 from $12 at BairdDentsply Sirona price target raised to $14 from $12 at Baird

Jonathan Block

Stifel Nicolaus

$13→$14

Hold

21.32%

Upside

Reiterated

02/27/26

Analysts Conflicted on These Healthcare Names: Arcutis Biotherapeutics (NASDAQ: ARQT), DENTSPLY SIRONA (NASDAQ: XRAY) and Edgewise Therapeutics (NASDAQ: EWTX)

Glen Santangelo

Barclays

$12

Sell

3.99%

Upside

Reiterated

02/27/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Alpha Teknova (NASDAQ: TKNO), Certara (NASDAQ: CERT) and DENTSPLY SIRONA (NASDAQ: XRAY)

David Saxon

Needham

―

Hold

―

Reiterated

02/27/26

Analysts Offer Insights on Healthcare Companies: Novavax (NASDAQ: NVAX), DENTSPLY SIRONA (NASDAQ: XRAY) and Viridian Therapeutics (NASDAQ: VRDN)

Brandon Vazquez

William Blair

―

Hold

―

Reiterated

02/27/26

Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (NASDAQ: XRAY), Solventum Corporation (NYSE: SOLV) and Privia Health Group (NASDAQ: PRVA)

Elizabeth Anderson CFA

Evercore ISI

$12→$15

Hold

29.98%

Upside

Reiterated

02/27/26

Dentsply Sirona price target raised to $15 from $12 at Evercore ISIDentsply Sirona price target raised to $15 from $12 at Evercore ISI

Jason Bednar

Piper Sandler

$13

Hold

12.65%

Upside

Reiterated

02/27/26

Piper Sandler Sticks to Their Hold Rating for DENTSPLY SIRONA (XRAY)

Allen Lutz

Bank of America Securities

$13→$17

Buy

47.31%

Upside

Upgraded

02/19/26

Dentsply Sirona upgraded to Buy from Neutral at BofADentsply Sirona upgraded to Buy from Neutral at BofA

Lilia-Celine (Lily) Lozada

J.P. Morgan

―

Hold

―

Reiterated

12/19/25

Analysts Offer Insights on Healthcare Companies: Novavax (NASDAQ: NVAX) and DENTSPLY SIRONA (NASDAQ: XRAY)

Erin Wright

Morgan Stanley

$14→$12

Hold

3.99%

Upside

Reiterated

11/07/25

Dentsply Sirona price target lowered to $12 from $14 at Morgan StanleyDentsply Sirona price target lowered to $12 from $14 at Morgan Stanley

Michael Cherny

Leerink Partners

$14.5→$13.5

Hold

16.98%

Upside

Reiterated

10/14/25

Leerink Partners Remains a Hold on DENTSPLY SIRONA (XRAY)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kevin Caliendo

UBS

$16→$18

Buy

55.98%

Upside

Reiterated

03/02/26

Dentsply Sirona price target raised to $18 from $16 at UBSDentsply Sirona price target raised to $18 from $16 at UBS

Michael Petusky

Barrington

$14→$17

Buy

47.31%

Upside

Reiterated

03/02/26

Dentsply Sirona price target raised to $17 from $14 at BarringtonDentsply Sirona price target raised to $17 from $14 at Barrington

Steven Valiquette

Mizuho Securities

$14→$16

Hold

38.65%

Upside

Reiterated

03/02/26

Dentsply Sirona price target raised to $16 from $14 at MizuhoDentsply Sirona price target raised to $16 from $14 at Mizuho

Unknown Analyst

Wells Fargo

Not Ranked

Wells Fargo

$13

Hold

12.65%

Upside

Reiterated

02/27/26

Wells Fargo Keeps Their Hold Rating on DENTSPLY SIRONA (XRAY)

Jeff Johnson

Robert W. Baird

$12→$14

Hold

21.32%

Upside

Reiterated

02/27/26

Dentsply Sirona price target raised to $14 from $12 at BairdDentsply Sirona price target raised to $14 from $12 at Baird

Jonathan Block

Stifel Nicolaus

$13→$14

Hold

21.32%

Upside

Reiterated

02/27/26

Analysts Conflicted on These Healthcare Names: Arcutis Biotherapeutics (NASDAQ: ARQT), DENTSPLY SIRONA (NASDAQ: XRAY) and Edgewise Therapeutics (NASDAQ: EWTX)

Glen Santangelo

Barclays

$12

Sell

3.99%

Upside

Reiterated

02/27/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Alpha Teknova (NASDAQ: TKNO), Certara (NASDAQ: CERT) and DENTSPLY SIRONA (NASDAQ: XRAY)

David Saxon

Needham

―

Hold

―

Reiterated

02/27/26

Analysts Offer Insights on Healthcare Companies: Novavax (NASDAQ: NVAX), DENTSPLY SIRONA (NASDAQ: XRAY) and Viridian Therapeutics (NASDAQ: VRDN)

Brandon Vazquez

William Blair

―

Hold

―

Reiterated

02/27/26

Analysts Offer Insights on Healthcare Companies: DENTSPLY SIRONA (NASDAQ: XRAY), Solventum Corporation (NYSE: SOLV) and Privia Health Group (NASDAQ: PRVA)

Elizabeth Anderson CFA

Evercore ISI

$12→$15

Hold

29.98%

Upside

Reiterated

02/27/26

Dentsply Sirona price target raised to $15 from $12 at Evercore ISIDentsply Sirona price target raised to $15 from $12 at Evercore ISI

Jason Bednar

Piper Sandler

$13

Hold

12.65%

Upside

Reiterated

02/27/26

Piper Sandler Sticks to Their Hold Rating for DENTSPLY SIRONA (XRAY)

Allen Lutz

Bank of America Securities

$13→$17

Buy

47.31%

Upside

Upgraded

02/19/26

Dentsply Sirona upgraded to Buy from Neutral at BofADentsply Sirona upgraded to Buy from Neutral at BofA

Lilia-Celine (Lily) Lozada

J.P. Morgan

―

Hold

―

Reiterated

12/19/25

Analysts Offer Insights on Healthcare Companies: Novavax (NASDAQ: NVAX) and DENTSPLY SIRONA (NASDAQ: XRAY)

Erin Wright

Morgan Stanley

$14→$12

Hold

3.99%

Upside

Reiterated

11/07/25

Dentsply Sirona price target lowered to $12 from $14 at Morgan StanleyDentsply Sirona price target lowered to $12 from $14 at Morgan Stanley

Michael Cherny

Leerink Partners

$14.5→$13.5

Hold

16.98%

Upside

Reiterated

10/14/25

Leerink Partners Remains a Hold on DENTSPLY SIRONA (XRAY)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering DENTSPLY SIRONA

3 Months

xxx

Success Rate

11/37 ratings generated profit

Average Return

-5.35%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 29.73% of your transactions generating a profit, with an average return of -5.35% per trade.

1 Year

Michael PetuskyBarrington

Success Rate

5/37 ratings generated profit

Average Return

-22.81%

a rating ―

Copying Michael Petusky's trades and holding each position for 1 Year would result in 13.51% of your transactions generating a profit, with an average return of -22.81% per trade.

2 Years

xxx

Success Rate

2/37 ratings generated profit

Average Return

-35.60%

a xxx

rating ―

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 5.41% of your transactions generating a profit, with an average return of -35.60% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

XRAY Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, XRAY has received 5 Buy Ratings, 13 Hold Ratings, and 1 Sell Ratings. XRAY average Analyst price target in the past 3 months is 14.90.

Each month's total comprises the sum of three months' worth of ratings.

XRAY Financial Forecast

XRAY Earnings Forecast

Next quarter’s earnings estimate for XRAY is $0.31 with a range of $0.22 to $0.40. The previous quarter’s EPS was $0.27. XRAY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year XRAY has Performed in-line its overall industry.

XRAY Sales Forecast

Next quarter’s sales forecast for XRAY is $846.67M with a range of $814.00M to $907.60M. The previous quarter’s sales results were $961.00M. XRAY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year XRAY has Performed in-line its overall industry.

XRAY Stock Forecast FAQ

What is XRAY’s average 12-month price target, according to analysts?

Based on analyst ratings, DENTSPLY SIRONA Inc’s 12-month average price target is 14.90.

What is XRAY’s upside potential, based on the analysts’ average price target?

DENTSPLY SIRONA Inc has 29.12% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is XRAY a Buy, Sell or Hold?

DENTSPLY SIRONA Inc has a consensus rating of Hold which is based on 3 buy ratings, 9 hold ratings and 1 sell ratings.

What is DENTSPLY SIRONA Inc’s price target?

The average price target for DENTSPLY SIRONA Inc is 14.90. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $18.00 ,the lowest forecast is $12.00. The average price target represents 29.12% Increase from the current price of $11.54.

What do analysts say about DENTSPLY SIRONA Inc?

DENTSPLY SIRONA Inc’s analyst rating consensus is a Hold. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of XRAY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

DENTSPLY SIRONA (XRAY) Stock Forecast & Price Target

XRAY Analyst Ratings

XRAY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering DENTSPLY SIRONA

XRAY Analyst Recommendation Trends

XRAY Financial Forecast

XRAY Earnings Forecast

XRAY Sales Forecast

XRAY Stock Forecast FAQ

Detailed List of Analyst Forecasts